DK2903600T3 - Virusholdig formulering og anvendelse deraf - Google Patents
Virusholdig formulering og anvendelse deraf Download PDFInfo
- Publication number
- DK2903600T3 DK2903600T3 DK13776991.5T DK13776991T DK2903600T3 DK 2903600 T3 DK2903600 T3 DK 2903600T3 DK 13776991 T DK13776991 T DK 13776991T DK 2903600 T3 DK2903600 T3 DK 2903600T3
- Authority
- DK
- Denmark
- Prior art keywords
- viral formulation
- viral
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306198 | 2012-10-02 | ||
PCT/EP2013/070590 WO2014053571A1 (en) | 2012-10-02 | 2013-10-02 | Virus-containing formulation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2903600T3 true DK2903600T3 (da) | 2022-09-26 |
Family
ID=47018930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13776991.5T DK2903600T3 (da) | 2012-10-02 | 2013-10-02 | Virusholdig formulering og anvendelse deraf |
Country Status (18)
Country | Link |
---|---|
US (1) | US10111947B2 (da) |
EP (1) | EP2903600B1 (da) |
JP (1) | JP6466332B2 (da) |
KR (1) | KR102181658B1 (da) |
CN (1) | CN104797242B (da) |
AU (1) | AU2013326548B2 (da) |
BR (1) | BR112015007314B1 (da) |
CA (1) | CA2887156C (da) |
DK (1) | DK2903600T3 (da) |
ES (1) | ES2928670T3 (da) |
HK (1) | HK1211206A1 (da) |
IL (1) | IL238064B (da) |
MX (1) | MX374287B (da) |
NZ (1) | NZ707328A (da) |
RU (1) | RU2686108C2 (da) |
SG (1) | SG11201502621XA (da) |
TW (1) | TWI690322B (da) |
WO (1) | WO2014053571A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11273127B2 (en) | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
US10555981B2 (en) | 2014-07-16 | 2020-02-11 | Transgene S.A. | Oncolytic virus for expression of immune checkpoint modulators |
US10517943B2 (en) | 2014-12-01 | 2019-12-31 | Transgene S.A. | Stable liquid vaccinia virus formulations |
CN107949397A (zh) * | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
US10639366B2 (en) | 2015-02-25 | 2020-05-05 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
SG11201807022XA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
WO2017160849A1 (en) * | 2016-03-14 | 2017-09-21 | Baylor College Of Medicine | Tc24-c4, a chagas disease vaccine antigen with improved stability and decreased aggregation |
BR112018069035A2 (pt) * | 2016-03-31 | 2019-01-29 | Takeda Vaccines Inc | composições e métodos para estabilização de alfavírus com formulações melhoradas |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
TW201825511A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
CA3061678A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
CA3067405A1 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides |
AU2018378590A1 (en) * | 2017-12-05 | 2020-06-25 | Beacon Therapeutics Limited | Formulation optimization for viral particles |
BR112020018117A2 (pt) | 2018-03-07 | 2020-12-22 | Transgene | Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune |
EP3814492A4 (en) | 2018-06-29 | 2022-02-23 | Wuhan Neurophth Biotechnology Limited Company | COMPOSITIONS AND METHODS OF TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY |
CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
AU2019336940A1 (en) | 2018-09-06 | 2021-03-11 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
US12252702B2 (en) | 2018-09-15 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
JP7557738B2 (ja) | 2018-10-30 | 2024-09-30 | 国立大学法人 東京大学 | がん治療のための腫瘍溶解性ウイルス |
IL284421B1 (en) | 2018-12-28 | 2025-01-01 | Transgene | M2-defective poxvirus |
WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
CA3170701A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Norcig A/S | Compositions improving poxvirus stability |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
CN115040656B (zh) * | 2022-07-05 | 2024-04-26 | 吉林惠康生物药业有限公司 | 狂犬疫苗冻干保护剂、应用和疫苗及其制备方法 |
TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2076787A5 (en) * | 1970-01-28 | 1971-10-15 | Merieux Inst | Lyophilisation stabiliser - for viruses contg potassium phosphate lactose and albumin |
US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
AU568666B2 (en) * | 1983-08-25 | 1988-01-07 | Thomas, G. | Production of phosphates from alkali-proecessed phosphate rock |
FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
WO1991002543A1 (en) * | 1989-08-15 | 1991-03-07 | Massachusetts Institute Of Technology | Stabilized vaccine compositions |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
WO1995031105A1 (en) | 1994-05-13 | 1995-11-23 | Thomas Jefferson University | A method of inducing an immune response using vaccinia virus recombinants |
EP0872249A4 (en) | 1995-03-17 | 2001-10-24 | Hisamitsu Pharmaceutical Co | GENE TRANSFER PREPARATION |
FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
CN1296096C (zh) | 2001-12-10 | 2007-01-24 | 巴法里安诺迪克有限公司 | 含痘病毒制剂和制备稳定的含有痘病毒组合物的方法 |
FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
EP1651272A1 (en) * | 2003-08-05 | 2006-05-03 | Fuji Photo Film B.V. | Use of recombinant or synthetic gelatin as a stabiliser in vaccines |
WO2005058356A2 (en) * | 2003-12-17 | 2005-06-30 | Wyeth | Methods for porducing storage stable viruses and immunogenic compositions thereof |
WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
CN100475268C (zh) | 2004-01-17 | 2009-04-08 | 上海三维生物技术有限公司 | 重组腺病毒冻干制剂及制备方法 |
NZ555501A (en) * | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
EP1928492B1 (en) * | 2005-09-01 | 2011-02-23 | Celgene Corporation | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
KR101772375B1 (ko) | 2005-09-07 | 2017-08-29 | 신라젠(주) | Gm-csf를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
US20100055069A1 (en) | 2006-04-21 | 2010-03-04 | Transgene S.A. | Hpv-18-based papillomavirus vaccines |
DK2530161T3 (da) | 2006-06-20 | 2018-06-06 | Transgene Sa | Fremgangsmåde til fremstilling af poxvira og poxvirussammensætninger |
AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
RU2503717C2 (ru) | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
RU2557312C2 (ru) | 2007-11-19 | 2015-07-20 | Трансжене С.А. | Поксвирусные онколитические векторы |
JP5855564B2 (ja) | 2009-05-12 | 2016-02-09 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | オルソポックスウイルスの製造および精製方法 |
RU2555346C2 (ru) | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
US20110243988A1 (en) * | 2009-10-01 | 2011-10-06 | Aridis Pharmaceuticals | Methods and Compositions for Stabilization of a Virus Vaccine |
US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
DK2898890T3 (da) | 2010-03-31 | 2019-11-25 | Stabilitech Biopharma Ltd | Stabilisering af viruspartikler |
RU2012144612A (ru) | 2010-04-15 | 2014-05-20 | Син Ниппон Байомедикал Лэборэтэриз, Лтд. | Способ и композиции для интраназальной доставки |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
-
2013
- 2013-10-01 TW TW102135548A patent/TWI690322B/zh active
- 2013-10-02 RU RU2015116539A patent/RU2686108C2/ru active
- 2013-10-02 CN CN201380060245.7A patent/CN104797242B/zh active Active
- 2013-10-02 US US14/433,142 patent/US10111947B2/en active Active
- 2013-10-02 ES ES13776991T patent/ES2928670T3/es active Active
- 2013-10-02 WO PCT/EP2013/070590 patent/WO2014053571A1/en active Application Filing
- 2013-10-02 AU AU2013326548A patent/AU2013326548B2/en active Active
- 2013-10-02 EP EP13776991.5A patent/EP2903600B1/en active Active
- 2013-10-02 KR KR1020157011647A patent/KR102181658B1/ko active Active
- 2013-10-02 SG SG11201502621XA patent/SG11201502621XA/en unknown
- 2013-10-02 DK DK13776991.5T patent/DK2903600T3/da active
- 2013-10-02 NZ NZ707328A patent/NZ707328A/en unknown
- 2013-10-02 CA CA2887156A patent/CA2887156C/en active Active
- 2013-10-02 JP JP2015535011A patent/JP6466332B2/ja active Active
- 2013-10-02 MX MX2015004290A patent/MX374287B/es active IP Right Grant
- 2013-10-02 BR BR112015007314-0A patent/BR112015007314B1/pt active IP Right Grant
-
2015
- 2015-03-31 IL IL238064A patent/IL238064B/en active IP Right Grant
- 2015-12-03 HK HK15111928.7A patent/HK1211206A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2887156C (en) | 2021-01-19 |
CA2887156A1 (en) | 2014-04-10 |
IL238064B (en) | 2019-07-31 |
HK1211206A1 (en) | 2016-05-20 |
SG11201502621XA (en) | 2015-05-28 |
KR102181658B1 (ko) | 2020-11-23 |
BR112015007314A2 (da) | 2017-08-15 |
TWI690322B (zh) | 2020-04-11 |
EP2903600B1 (en) | 2022-08-31 |
US20150250869A1 (en) | 2015-09-10 |
BR112015007314B1 (pt) | 2023-05-09 |
US10111947B2 (en) | 2018-10-30 |
JP6466332B2 (ja) | 2019-02-06 |
IL238064A0 (en) | 2015-05-31 |
AU2013326548B2 (en) | 2018-07-19 |
JP2015531387A (ja) | 2015-11-02 |
CN104797242B (zh) | 2019-10-01 |
TW201417820A (zh) | 2014-05-16 |
CN104797242A (zh) | 2015-07-22 |
EP2903600A1 (en) | 2015-08-12 |
MX374287B (es) | 2025-03-06 |
AU2013326548A1 (en) | 2015-05-14 |
WO2014053571A1 (en) | 2014-04-10 |
KR20150087206A (ko) | 2015-07-29 |
RU2686108C2 (ru) | 2019-04-24 |
ES2928670T3 (es) | 2022-11-22 |
RU2015116539A (ru) | 2016-11-27 |
MX2015004290A (es) | 2016-01-20 |
NZ707328A (en) | 2018-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
DK2920313T3 (da) | Rekombinante adenovira og anvendelse deraf | |
HK1209079A1 (zh) | 催化的劑型和配方 | |
DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
DK2850202T3 (da) | Fremgangsmåder og grupper | |
DK2841429T3 (da) | Tetrazolinonforbindelser og anvendelse deraf som pesticider | |
DK3196022T3 (da) | Trykningssystem og fremgangsmåde | |
HUE040111T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
SI3725778T1 (sl) | Formulacije enzalutamida | |
HK1203493A1 (en) | Substituted azabicycles and use thereof | |
DK2872419T3 (da) | Fordelingsbeholder og tilsvarende fremgangsmåde | |
DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
DK3326642T3 (da) | Langtidsvirkende koagulationsfaktorer og brugen deraf | |
DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
DK3392252T3 (da) | Pyrimido-pyridazinonforbindelser og deres anvendelse | |
DK2809669T3 (da) | Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika | |
CY2200004T2 (el) | Σκευασματα δαπτομυκινης και χρησεις αυτων |